Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

eet as at December 31, 2012 and are sourced from Elan's 20-F SEC filing on February 12, 2013 for the financial year ended December 31, 2012. This calculation has been amended from the calculation included in Appendix II of the Proposal Announcement to include the impact of the US$29.9 million funding provided to Janssen AI in January 2013 (after the end of Elan's last reported financial year).

All amounts contained within this document referred to by "US$" and "c" refer to the US dollar and US cents.

Any reference to "subsidiary undertaking", "associated undertaking" and "undertaking" have the meanings given by the European Communities (Companies: Group Accounts) Regulations, 1992.

Any reference to "subsidiary" has the meaning given to it by Section 155 of the Irish Companies Act 1963, as amended.

Any references to any provision of any legislation shall include any amendment, modification, re-enactment or extension thereof. Any reference to any legislation is to Irish legislation unless specified otherwise.

Words importing the singular shall include the plural and vice versa and words supporting the masculine shall include the feminine or neuter gender.

[1] Net cash calculated in Appendix VI (including the Janssen AI funding commitment relating to bapineuzumab).

[2] Per Elan stock numbers in this section are based on 602.0 million fully diluted shares outstanding at the Proposal Price, as calculated in Appendix VI.

[3] 2020 being the time at which the primary U.S. patent relating to Tysabri and covering the relevant humanized antibody expires. Extracted from Elan's 20-F SEC filing on February 12, 2013 for the financial year ended December 31, 2012.

[4] Referenced in CallStreet transcript of the Tysabri Conference Call on February 6, 2013.

[5] On the basis of Elan's announcement of its results for the 2012 financial year made on February 6, 2013.

[6] US$60-80 million expected this year,
'/>"/>

SOURCE RP Management, LLC
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
6. AVANIR Pharmaceuticals To participate in two conferences in March
7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan ... human cord blood stem cell banking and therapeutics, announced ... the No. 16 Acorn Stairlifts Indy car driven by ... the remainder of the IZOD IndyCar 2013 season.   ... will work to support awareness of umbilical cord blood ...
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
(Date:5/23/2013)... , May 23, 2013 BioTrends Research ... advisory firms for specialized biopharmaceutical issues, finds that, ... infectious disease specialists reported that in the past ... intentionally delaying treatment) in anticipation of the next ... months ago, when only 6 percent reported that ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... molecules that appear in the central region of ,macromolecules ... atom ,at their center that determines their specific function. ... molecular electronics lies in their "ease of transfer ,electrons ... the work at the Nanomaterials and Nanotechnology Research Center ...
... Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that ... Friday, September 9, 2011 at 10:55 a.m. EDT (7:55 a.m. ... Hotel in Boston.  Steve Worland, Ph.D., President and Chief Executive ... its clinical development programs, setrobuvir and ANA773. Dr. ...
... (NYSE Amex: CUR ) announced that President ... Stifel Nicolaus Annual Healthcare Conference on Wednesday, September 7 ... opportunities and advancements in neural stem cell pharmaceuticals and ... the ongoing ALS trial at Emory University. ...
Cached Biology Technology:The quantum tunneling effect leads electron transport in porphyrins 2Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 2Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 3Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference 2Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference 3
(Date:5/24/2013)... 500 leading water scientists from around the world today ... the short span of one or two generations, the ... be living under the handicap of severe pressure on ... there is no substitute. This handicap will be self-inflicted ... bluntly pointed to chronic underlying problems led by mismanagement ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... world,s most popular fruit, can be made both better-tasting ... varieties. , "Working with GM tomatoes that are ... a specific compound, allows us to pinpoint exactly how ... from the John Innes Centre. , The research could ... and shelf life characteristics because even higher levels of ...
Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2
... jumps out of the bushes, youre still surprised. But your ... have begun to distinguish the circuitry in the brains emotion ... aversive or reward valence of a stimulus. C. Daniel ... 2007 issue of the journal Neuron, published by Cell Press. ...
... trenches in the First World War, but nearly a century ... discovered that phosgene is present in significant quantities in the ... well after the Second World War, but its continued presence ... used in the chemical industry. A team, including ...
... emissions should quickly reduce mercury levels in lake fish, ... the Proceedings of the National Academy of Science. The ... rates relevant to atmospheric deposition resulted in a significant ... only three years. This is good news. ...
Cached Biology News:How the brain handles surprise, good and bad 2Scientists in first global study of 'poison' gas in the atmosphere 2New study shows fish respond quickly to changes in mercury deposition 2New study shows fish respond quickly to changes in mercury deposition 3
...
SHEEP ANTI ESCHERICHIA COLI...
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Multi-Sample Freezing-point Osmometer for 30 L samples, featuring 24-position turntable. Provides up to 30 minutes ... and software for statistical analysis and record keeping. RS-232 port. ... ... ...
Biology Products: